ImmuPharma PLC (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the further analysis of the results from its pivotal Phase III trial of Lupuzor and final results. Tim talks us
Update on Phase 3 trial data and Final Results NORTHLAND VIEW ImmuPharma announced further data analysis on its Phase 3 trial data, as well as its final results for FY2017.
Tim McCarthy, Chairman added: “In this study Lupuzor(TM) has demonstrated a superior response rate over placebo and confirmed its exceptional safety profile. We believe this gives Lupuzor(TM) a compelling product
ImmuPharma’s Tim McCarthy discusses the topline results of their Lupuzor Phase III trial in this exclusive interview with DirectorsTalk
Immupharma Plc (LON:IMM) Chairman Tim McCarthy talks to DirectorsTalk about the topline results of the Lupuzor™ pivotal phase III. Tim provides his perspective on the data issued to the market,
Tim McCarthy, Chairman added: “Lupuzor(TM) has demonstrated, in this study, a superior response rate over placebo and its exceptional safety, giving it, we believe, a compelling product profile. Whilst we
ImmuPharma PLC (LON:IMM), the specialist drug discovery and development company, has today announced that it has with immediate effect appointed Bryan, Garnier & Co. Limited as its joint corporate broker to
Lupuzor Pivotal Phase III Study Update NORTHLAND VIEW ImmuPharma has been informed by Simbec-Orion, the contract research organisation (CRO) conducting the Company’s Phase III trial for Lupuzor™, that the ‘database
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company announced this morning that it has been informed by Simbec-Orion, the contract research organisation conducting our Lupuzor™ pivotal Phase III
ImmuPharma PLC (LSE: IMM), specialist drug discovery and development company, this morning told DirectorsTalk that Tim McCarthy, Chairman, will be presenting at an investor evening hosted by Turner Pope Investments
© 2023 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
